Altimmune, Inc. (ALT) vs Oculis Holding AG (OCS)

Altimmune, Inc. and Oculis Holding AG are both Biotechnology companies. Altimmune, Inc. and Oculis Holding AG are of similar size ($593.3M and $579.5M). Altimmune, Inc. grew revenue faster over the last twelve months: 130.0% against 65.8%. Altimmune, Inc. has the higher net margin (0.00% vs −6,870.1%) and the lower return on invested capital (−34.3% vs 0.00%). Across the 16 metrics below, Altimmune, Inc. leads on 11 and Oculis Holding AG on 5.

Valuation

Metric ALT OCS Biotechnology median
P/E n/m n/m 7.88
P/S 12,336.04 385.70 11.47
P/B 1.20 2.05 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 6,007.86 191.30 10.73
Earnings yield (25.49%) (18.77%) (28.84%)
Free cash flow yield (13.53%) (14.56%) (23.03%)

Profitability

Metric ALT OCS Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% (7,383.66%) 0.00%
Net margin 0.00% (6,870.05%) 0.00%
Free cash flow margin 0.00% (5,525.64%) 0.00%
Return on equity (28.87%) (44.87%) (57.72%)
Return on assets (25.58%) (37.69%) (49.22%)
Return on invested capital (34.30%) 0.00% 0.00%

Growth

Metric ALT OCS Biotechnology median
Revenue growth (TTM) 130.00% 65.83% 5.64%
EPS growth (last fiscal year) 25.37% 5.39% —
Revenue growth, 5-year CAGR (65.33%) — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ALT OCS Biotechnology median
Debt to equity 0.07 0.01 0.00
Current ratio 26.78 8.35 4.73
Net debt to EBITDA 2.49 2.60 0.96

Dividend

Metric ALT OCS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric ALT OCS Biotechnology median
Market cap 593.28m 579.54m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack